Almirall (E2Z0) Stock Overview

Operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. More details

E2Z0 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	2/6
Financial Health	6/6
Dividends	1/6

Rewards

Trading at 54.7% below our estimate of its fair value

Earnings are forecast to grow 33.04% per year

Became profitable this year

Risk Analysis

No risks detected for E2Z0 from our risk checks.

E2Z0 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Almirall, S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Almirall
Historical stock prices
Current Share Price	€12.37
52 Week High	€12.69
52 Week Low	€10.98
Beta	0.17
1 Month Change	3.65%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	9.96%

Recent updates

Shareholder Returns

	E2Z0	DE Pharmaceuticals	DE Market
7D	1.4%	0.8%	0.1%
1Y	n/a	9.5%	13.5%

Return vs Industry: Insufficient data to determine how E2Z0 performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how E2Z0 performed against the German Market.

Price Volatility

Is E2Z0's price volatile compared to industry and market?
E2Z0 volatility
E2Z0 Average Weekly Movement	4.6%
Pharmaceuticals Industry Average Movement	6.4%
Market Average Movement	5.1%
10% most volatile stocks in DE Market	12.4%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: E2Z0 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine E2Z0's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1943	2,084	Carlos Gallardo Piqué	www.almirall.com

Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, nervous, and respiratory system; dermatologicals; genito urinary system and sex hormones; immunostimulants; metabolism; and systematic hormonal preparations. It has a multi-target partnership with Etherna to research and develop mRNA-based therapies for medical dermatology.

Almirall, S.A. Fundamentals Summary

How do Almirall's earnings and revenue compare to its market cap?
E2Z0 fundamental statistics
Market cap	€2.75b
Earnings (TTM)	€42.05m
Revenue (TTM)	€1.09b

65.5x

P/E Ratio

2.5x

P/S Ratio

Is E2Z0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
E2Z0 income statement (TTM)
Revenue	€1.09b
Cost of Revenue	€271.93m
Gross Profit	€813.10m
Other Expenses	€771.05m
Earnings	€42.05m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

Feb 23, 2026

Earnings per share (EPS)	0.20
Gross Margin	74.94%
Net Profit Margin	3.88%
Debt/Equity Ratio	22.9%

How did E2Z0 perform over the long term?

See historical performance and comparison

Dividends

1.4%

Current Dividend Yield

188%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/12/28 15:35
End of Day Share Price	2025/12/23 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Almirall, S.A. is covered by 26 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Guilherme Sampaio	Banco BPI, S.A.
Flora Mericia Trindade	Banco BPI, S.A.
Luis Arredondo	Banco de Sabadell. S.A.

Almirall, S.A.DB:E2Z0 Stock Report